NCT06259136 Palliative Care Yields Cancer Wellbeing Support
| NCT ID | NCT06259136 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Radboud University Medical Center |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,050 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,050 participants in total. It began in 2024-06-01 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to evaluate the effectiveness of a programme for transitional palliative cancer care (Pal-Cycles) in seven countries (the Netherlands, Germany, United Kingdom, Hungary, Poland, Romania and Portugal) and its consequent effects on the number of readmissions into hospital. The main hypothesis for the study is: that fewer people in the intervention arm of the study will require hospital re admission than those having usual care. Participants will be asked to fill in questionnaires regarding their quality of care and quality of life.
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 years or above * Patients diagnosed with advanced cancer * Patients that are expected to develop or already may have palliative care needs * Patients who are in transition from curative (hospital) to palliative care (community care) Exclusion Criteria: * People with cancer unable or unwilling to provide consent to participate in the study
Contact & Investigator
Jeroen Hasselaar
PRINCIPAL INVESTIGATOR
Radboud University Medical Center (Radboudumc)
Frequently Asked Questions
Who can join the NCT06259136 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06259136 currently recruiting?
Yes, NCT06259136 is actively recruiting participants. Contact the research team at pippa.vandenbrand@radboudumc.nl for enrollment information.
Where is the NCT06259136 trial being conducted?
This trial is being conducted at Nijmegen, Netherlands.
Who is sponsoring the NCT06259136 clinical trial?
NCT06259136 is sponsored by Radboud University Medical Center. The principal investigator is Jeroen Hasselaar at Radboud University Medical Center (Radboudumc). The trial plans to enroll 1,050 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.